Only one out of every five adults with cirrhosis in safety-net health systems receive guideline-concordant hepatocellular carcinoma surveillance.Rates have dropped significantly since before the COVID pandemic, according to data published in JAMA Network Open, and researchers have not observed a rebound after.“Even when you look at the period before the pandemic, what we describe as baseline, liver cancer screening was…
Source: Healio News
